Characterizing Effects of Erenumab on Patients with Menstrually-Related Migraines

Brief description of study

A retrospective observational study identifying the effects of CGRP antagonist, erenumab-aooe (Aimovig), on migraine in female patients between the age of 18 to 55. They will be asked to complete a questionnaire to determine if these agents are an effective treatment for menstrually-related migraines.

Clinical Study Identifier: s19-01534
Principal Investigator: Adelene E. Jann.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.